Ratings Alliance Pharma plc

Equities

APH

GB0031030819

Delayed London S.E. Other stock markets 01:35:56 02/05/2024 pm IST			5-day change	1st Jan Change
33.78 ^GBX	-0.65%		-4.85%	-16.59%

22/04	EARNINGS: Lok'n Store has "positive but muted" growth as Shurgard bids	AN
22/04	Alliance Pharma plc Announces Delay in Publication of Preliminary Earnings Results for the Year Ended December 31, 2023	CI

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's attractive earnings multiples are brought to light by a P/E ratio at 9.96 for the current year.
The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

The company is in debt and has limited leeway for investment
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ALLIANCE PHARMA PLC	-16.59%	229M		C+
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.41%	43.18B		B-
OTSUKA HOLDINGS CO., LTD.	+20.67%	22.59B		B+
SANDOZ GROUP AG	+15.59%	14.56B		-
ZYDUS LIFESCIENCES LIMITED	+41.72%	11.5B		B
ONO PHARMACEUTICAL CO., LTD.	-8.37%	6.93B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.36B		B+
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.27%	4.81B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes